JPMorgan Chase & Co’s Edgewise Therapeutics EWTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.02M | Sell |
77,616
-13,752
| -15% | -$180K | ﹤0.01% | 3711 |
|
|
2025
Q1 | $2.01M | Sell |
91,368
-33,067
| -27% | -$727K | ﹤0.01% | 3249 |
|
|
2024
Q4 | $3.32M | Sell |
124,435
-34,071
| -21% | -$910K | ﹤0.01% | 3063 |
|
|
2024
Q3 | $4.23M | Buy |
158,506
+94,147
| +146% | +$2.51M | ﹤0.01% | 2734 |
|
|
2024
Q2 | $1.16M | Buy |
64,359
+21,526
| +50% | +$388K | ﹤0.01% | 3422 |
|
|
2024
Q1 | $781K | Buy |
42,833
+2,770
| +7% | +$50.5K | ﹤0.01% | 3709 |
|
|
2023
Q4 | $438K | Sell |
40,063
-441
| -1% | -$4.83K | ﹤0.01% | 3985 |
|
|
2023
Q3 | $232K | Buy |
40,504
+4,926
| +14% | +$28.2K | ﹤0.01% | 4152 |
|
|
2023
Q2 | $276K | Buy |
35,578
+4,198
| +13% | +$32.5K | ﹤0.01% | 4100 |
|
|
2023
Q1 | $210K | Buy |
31,380
+7,063
| +29% | +$47.3K | ﹤0.01% | 4299 |
|
|
2022
Q4 | $217K | Buy |
24,317
+4,520
| +23% | +$40.3K | ﹤0.01% | 4172 |
|
|
2022
Q3 | $195K | Sell |
19,797
-1,312
| -6% | -$12.9K | ﹤0.01% | 4184 |
|
|
2022
Q2 | $168K | Sell |
21,109
-6,057
| -22% | -$48.2K | ﹤0.01% | 4397 |
|
|
2022
Q1 | $263K | Buy |
27,166
+5,156
| +23% | +$49.9K | ﹤0.01% | 4305 |
|
|
2021
Q4 | $337K | Buy |
22,010
+14,531
| +194% | +$222K | ﹤0.01% | 4271 |
|
|
2021
Q3 | $124K | Sell |
7,479
-2,644
| -26% | -$43.8K | ﹤0.01% | 4621 |
|
|
2021
Q2 | $216K | Buy |
+10,123
| New | +$216K | ﹤0.01% | 4459 |
|